Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
NEW YORK, March 24, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Natus Medical Incorporated (NASDAQ:BABY) securities between October 16, 2015 and April 3, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/natus-medical-incorporated. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) as a result, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis.
If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/natus-medical-incorporated.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
